News >

Expert Highlights Potential of Erdafitinib in Urothelial Carcinoma

Brandon Scalea
Published: Friday, Aug 10, 2018

Arlene O. Siefker-Radtke, MD
Arlene O. Siefker-Radtke, MD
Erdafitinib, a novel pan-FGFR inhibitor, demonstrated promising activity in patients with urothelial cancer who harbor FGFR alterations, according to recent data from a phase II trial.

Urothelial cancer is an aggressive disease that generally leaves a patient with a grim prognosis, said Arlene O. Siefker-Radtke, MD; however, erdafitinib might be the key agent to providing FGFR-mutant patients with the necessary therapy.

More than 40% of patients with metastatic or unresectable urothelial carcinoma responded to treatment with erdafitinib, according to the phase II findings presented by Siefker-Radtke at the 2018 ASCO Annual Meeting. Overall, 40 out of 99 patients responded to treatment with erdafitinib. An additional 39 patients had stable disease. Responses occurred in patients who had no prior exposure to chemotherapy, as well as those who had progressed or relapsed after previous treatment. Response rates were similar in patients with or without visceral metastases.

Patients were orally treated with 8 mg daily with uptitration to 9 mg daily. Enrolled patients had progressed on 1 or more prior lines of therapy or within 12 months of neoadjuvant therapy, or were ineligible for first-line platinum-based chemotherapy. Patients with prior exposure to immunotherapy were also included.

The FDA granted erdafitinib a breakthrough therapy designation in March 2018 for the treatment of patients with metastatic urothelial carcinoma.

FGFR alterations occur in 15% to 20% of metastatic urothelial carcinomas and 40% to 70% of non-muscle invasive bladder cancers. These tumor types tend to be immunologically cold and, therefore, do not respond to immunotherapy, Siefker-Radtke said.

In an interview with OncLive, Siefker-Radtke, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, clinical co-leader, Bladder Spore Executive Committee, discussed the promise of erdafitinib in patients with urothelial carcinoma.

OncLive: Please provide some background for this trial.

Siefker-Radtke: Bladder cancer is really no longer just one disease. We have been treating it that way for several decades now. What we are learning is that there are different types of bladder cancers, some that respond better to chemotherapy, some that respond better to immunotherapy, and some that appear immunologically cold. In fact, the FDA just announced they are no longer accruing patients with low PD-L1 expression to the frontline single-agent immunotherapy trials. Therefore, there is growing evidence that we need more options for our patients with bladder cancer.

FGFR3 tumors may reflect one of those unmet needs. There are some early data that suggest these tumor types may be more immunologically cold. There is a new treatment called erdafitinib that targets FGFR-altered tumors. We saw FGFR3 alterations in approximately 15% to 20% of patients with metastatic urothelial cancer. We saw them at a higher frequency—in the 30% range—for patients with metastatic upper-tract urothelial cancers. In earlier-stage disease, the frequency may be as high as 50% or 60% in patients with low-grade, low-stage urothelial cancers. Finding a treatment that can target these may provide us with better control for our patients.

Erdafitinib is a pan-FGFR inhibitor and it targets FGFR 1, 2, 3, and 4. It is a very good inhibitor to target these alternations. It also has lysosomal uptake, which may enhance sustained intracellular release, impacting the good activity of this treatment. Therefore, the rationale of this trial was to study the use of erdafitinib in a group of patients with metastatic and mostly previously treated urothelial tumors who had need of a new agent. Some of them received prior immunotherapy and some of them had chemotherapy.

The first part of the trial was randomized. We did not know whether continuous dosing was better versus intermittent dosing. As a result of the early part of the trial, continuous dosing was selected, and we were even able to up titration from 8 mg/day to 9 mg/day if patients did not achieve a certain target phosphorous level. The trial data suggest that there is some clinical activity, and the study met its primary endpoint. This was out of 99 patients in the select phase II cohort.

The therapy was very well tolerated and very few patients discontinued treatment because of side effects. The most common reason for discontinuing was due to eventual progression of disease…The [median] progression-free survival was around 5.6 months, and the median overall survival was 13.8 months.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication